treatment

Medications that can promote the repair of the myelin sheath — the protective coating around nerve cells in the body — may also help limit nerve damage in multiple sclerosis (MS), according to a new analysis of data from a small clinical trial testing an anticancer therapy called bexarotene…

In progressive forms of multiple sclerosis (MS), treatment with estrogen hormones such as estradiol may help reduce inflammation and nerve damage — especially among patients for whom the disease may be triggered or worsened by viral infections — a mouse study has found. U.S. researchers investigating the impact of sex…

Autologous hematopoietic stem cell transplant (aHSCT) could slow disease progression in people with relapsing-remitting multiple sclerosis (RRMS), according to a study tracking MS patients in Sweden. The procedure was associated with sustained reductions in biomarkers linked to progressive MS. The results also showed that a significant portion of patients…

Experts are calling for tailored strategies to enhance the diagnosis, treatment, and monitoring of older people with multiple sclerosis (MS). As people with MS live longer, age-related biological changes increasingly complicate diagnosing and managing the disease in older adults. No universal framework currently guides how to address these unique…

Fumarate-based therapies like Tecfidera (dimethyl fumarate) and Vumerity (diroximel fumarate) are equally effective among Black, Hispanic, Asian, and white adults with relapsing forms of multiple sclerosis (MS) in the U.S., the largest real-world study of its kind shows. “The findings of this study suggest that fumarate medicines…

Fenebrutinib significantly reduced the occurrence of new brain lesions with active inflammation in people with relapsing multiple sclerosis (MS), a Phase 2 clinical trial found. In the open-label extension portion of the FENopta trial (NCT05119569), disease activity “remained very low” for nearly one year, researchers wrote, with 98%…

A global clinical trial has been launched to evaluate the oral therapy candidate BMS-986368 for treating spasticity — muscle stiffness and spasms — in people with multiple sclerosis (MS). The Phase 2 study (NCT06782490), called BALANCE-MSS-1, will enroll about 200 adults with MS who have experienced spasticity…

Mesenchymal stem cell (MSC) therapy is safe and well tolerated, and leads to improvements in disability and a reduction in lesion burden in people with multiple sclerosis (MS), according to a review of published studies. MSC treatments also reduced levels of biomarkers associated with nerve damage and inflammation,…

Vibration therapy, which provides mechanical stimulation to activate muscles and sensory receptors, may offer a promising new approach for easing fatigue in people with multiple sclerosis (MS), according to new data from a clinical trial. Patients who received vibration therapy reported reduced perceived fatigue and also showed significant gains…

Blood levels of a protein called GFAP, which reflects the activation and damage to support cells in the brain and spinal cord, may help predict disease severity and the response to treatment with relapsing forms of multiple sclerosis (MS), according to a new analysis of clinical trial data. “This…

Treatment with neural stem cells, which have the ability to differentiate into neurons and other supportive cells of the nervous system, was safe and significantly boosted myelin repair in spinal cord lesions in a mouse model of multiple sclerosis (MS), a study showed. The stem cells were able to…

People with multiple sclerosis (MS) who are treated with formulations of botulinum toxin to manage spasticity generally report being satisfied with the treatment, a new study reports. The study examined the use of these formulations in people with spasticity due to a number of conditions, the most common…

Quantum Biopharma filed a U.K. innovation passport application to streamline the development and review of Lucid-21-302 (Lucid-MS), a therapy designed to promote myelin repair in people with multiple sclerosis (MS). The submission, made via Quantum’s Australian subsidiary, Huge Biopharma Australia, marks the first step to entering the U.K.’s Innovative…

Nearly two-thirds of people with multiple sclerosis (MS) who underwent a stem cell transplant showed no signs of confirmed disability progression five years later, according to a study tracking MS patients in the U.K. The results were generally better for people with relapsing-remitting MS (RRMS), but nearly half…

A team of U.S. and Chinese researchers appears to have unlocked a novel way to stop T-cells from attacking the body in multiple sclerosis (MS) and other autoimmune diseases, according to the findings of a new study. An experimental therapy called BiTS, developed based on these new molecular insights,…

Researchers at the Karolinska Institute in Sweden said they have identified 18 new potential protein drug targets to treat multiple sclerosis (MS) using an integrative analytical approach. A drug target is a molecule, typically a protein, within the body that’s often involved in disease processes. Some of the newly…

Anti-CD20 therapies, a type of treatment approved for multiple sclerosis (MS), alter the activity of several types of immune cells, including increasing the levels of certain anti-inflammatory immune cells. That’s according to the study “Transcriptomic profiling after B cell depletion reveals central and peripheral immune cell…

Scientists have made significant advances in treating multiple sclerosis (MS) in recent decades, with a number of treatments for the neurodegenerative disease approved or in development. But one issue that’s been more challenging to address, researchers say, is MS quiet progression — when there aren’t new visible lesions…

In healthy adults, a single low dose of Immutep’s immunosuppressive candidate IMP761 continues to be safe and appears to reduce the activity of T-cells — immune cells that become overactive in multiple sclerosis (MS) and other autoimmune diseases. This is according to data from an ongoing Phase…

Two of three groups — one composed of people with progressive forms of multiple sclerosis (MS), and the other comprising healthy volunteers — have been fully enrolled in a Phase 1b clinical trial that’s testing a new anti-inflammatory drug being developed by Contineum Therapeutics. The Phase 1b…

Older men with multiple sclerosis (MS) who use medicines that reduce the levels of androgens, or male sex hormones, experience sustained or increased disease activity instead of the expected decreases that typically happen with advancing age, a small study suggests. According to the team, such disease activity was “particularly”…

A new low-cost version of Tecfidera, a widely used oral therapy for relapsing forms of multiple sclerosis (MS), is now available in the U.S. for a fraction of the typical cost. Launched by Civicascript, this generic form of dimethyl fumarate is expected to significantly improve access to…

More than 90% of relapsing-remitting multiple sclerosis (RRMS) patients who received Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium have not experienced confirmed disability worsening after nearly three years. That’s according to new data from the EMPhASIS Phase 2 clinical trial (NCT03846219) and its open-label extension (OLE)…

A CAR T-cell therapy from Iaso Biotherapeutics was tolerated well and led to marked improvements in disability for three people with progressive forms of multiple sclerosis (MS), according to early data from a Phase 1 clinical trial. After a single dose of equecabtagene autoleucel, patients saw rapid and…

Hormone therapies used in gender-affirming care for transgender people may affect disease activity in multiple sclerosis (MS), a small new study reports, although its researchers cautioned that more research is are needed to more comprehensively assess its impact in MS. The study, “Gender-affirming interventions and prognosis…

An experimental medicine, 2-D08, boosts motor function in mice and primate models of multiple sclerosis (MS) by repairing the myelin sheath, the protective coating on nerve fibers that’s damaged in people with the neurodegenerative condition, a study showed. 2-D08 also outperformed the approved therapy dalfampridine, sold as Ampyra…

Aetna Healthcare has agreed to reimburse Helius Medical Technologies’ PoNS device, short for Portable Neuromodulation Stimulator, which uses electrical stimulation to improve walking in people with multiple sclerosis (MS). The policy covers PoNS at an out-of-network negotiated price of $18,350, making Aetna, one of the largest private health…

Enrollment is now complete in the twin Phase 3 clinical trials testing Immunic Therapeutics‘ oral small molecule vidofludimus calcium in adults with relapsing forms of multiple sclerosis (MS). ENSURE-1 (NCT05134441) has enrolled 1,121 patients and ENSURE-2 (NCT05201638) has enrolled 1,100 patients at more than 100…

Body mass index (BMI), a measure commonly used measure of body fat based on a person’s height and weight, does not seem to affect responses to stem cell transplant in people with multiple sclerosis (MS), a study found. While the efficacy of an autologous transplant — one that…

Ocrevus (ocrelizumab) appears to be safe and effective for children and adolescents with multiple sclerosis (MS), according to real-world data from Kuwait. After about 15 months of treatment, more than 90% of patients with pediatric-onset MS (POMS) remained free of relapses, and most also showed no new…